[HTML][HTML] Plasma cytokines in women with chronic fatigue syndrome
MA Fletcher, XR Zeng, Z Barnes, S Levis… - Journal of translational …, 2009 - Springer
MA Fletcher, XR Zeng, Z Barnes, S Levis, NG Klimas
Journal of translational medicine, 2009•SpringerAbstract Background Chronic Fatigue Syndrome (CFS) studies from our laboratory and
others have described cytokine abnormalities. Other studies reported no difference between
CFS and controls. However, methodologies varied widely and few studies measured more
than 4 or 5 cytokines. Multiplex technology permits the determination of cytokines for a large
panel of cytokines simultaneously with high sensitivity and with only 30 ul of plasma per
sample. No widely accepted laboratory test or marker is available for the diagnosis or …
others have described cytokine abnormalities. Other studies reported no difference between
CFS and controls. However, methodologies varied widely and few studies measured more
than 4 or 5 cytokines. Multiplex technology permits the determination of cytokines for a large
panel of cytokines simultaneously with high sensitivity and with only 30 ul of plasma per
sample. No widely accepted laboratory test or marker is available for the diagnosis or …
Background
Chronic Fatigue Syndrome (CFS) studies from our laboratory and others have described cytokine abnormalities. Other studies reported no difference between CFS and controls. However, methodologies varied widely and few studies measured more than 4 or 5 cytokines. Multiplex technology permits the determination of cytokines for a large panel of cytokines simultaneously with high sensitivity and with only 30 ul of plasma per sample. No widely accepted laboratory test or marker is available for the diagnosis or prognosis of CFS. This study screened plasma factors to identify circulating biomarkers associated with CFS.
Methods
Cytokines were measured in plasma from female CFS cases and female healthy controls. Multiplex technology provided profiles of 16 plasma factors including the pro -inflammatory cytokines: tumor necrosis factor α (TNFα), lymphotoxin α (LTα), interleukin (IL) - IL-Iα, IL-1β, IL-6; TH1 cytokines: interferon γ (IFNγ), IL-12p70, IL-2, IL-15; TH2: IL-4, IL-5; TH17 cytokines, IL-17 and IL-23; anti-inflammatory cytokines IL-10, IL-13; the inflammatory mediator and neutrophil attracting chemokine IL-8 (CXCL8). Analysis by receiver operating characteristic (ROC) curve assessed the biomarker potential of each cytokine.
Results
The following cytokines were elevated in CFS compared to controls: LTα, IL-1α, IL-1β, IL-4, IL-5, IL-6 and IL-12. The following cytokines were decreased in CFS: IL-8, IL-13 and IL-15. The following cytokines were not different: TNFα, IFNγ, IL-2, IL-10, IL-23 and IL-17. Applying (ROC) curve analyses, areas under the curves (AUC) for IL-5 (0. 84), LTα (0.77), IL-4 (0.77), IL-12 (0.76) indicated good biomarker potential. The AUC of IL-6 (0.73), IL-15 (0.73), IL-8 (0.69), IL-13 (0.68) IL-1α (0.62), IL-1β (0.62) showed fair potential as biomarkers.
Conclusion
Cytokine abnormalities are common in CFS. In this study, 10 of 16 cytokines examined showed good to fair promise as biomarkers. However, the cytokine changes observed are likely to more indicative of immune activation and inflammation, rather than specific for CFS. As such, they are targets for herapeutic strategies. Newer techniques allow evaluation of large panels of cytokines in a cost effective fashion.
Springer